Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7633092 | 0.98 | IDO1 (0.38) | GAAL3MBTL1IDO1HIF1AALDH1A1 | |
| Bromide SCHEMBL2445980 | 0.98 | IDO1 (0.38) | GAAL3MBTL1IDO1HIF1AALDH1A1 | |
| Bromide SCHEMBL3322091 | 0.98 | IDO1 (0.38) | GAAL3MBTL1IDO1HIF1AALDH1A1 | |
| SCHEMBL31321441 | 0.97 | GAA (0.38) | GAAL3MBTL1IDO1HIF1AALDH1A1 | |
| Bromide SCHEMBL10533526 | 0.95 | IDO1 (0.37) | GAAL3MBTL1IDO1HIF1AALDH1A1 | |
| Iodide SCHEMBL6591776 | 0.95 | GAA (0.36) | GAAL3MBTL1IDO1HIF1AALDH1A1 | |
| SCHEMBL29515524 | 0.95 | IDO1 (0.39) | GAAL3MBTL1IDO1HIF1AALDH1A1 | |
| Water SCHEMBL6634553 | 0.95 | GAA (0.36) | GAAL3MBTL1IDO1HIF1AALDH1A1 | |
| Bromide SCHEMBL3389414 | 0.95 | HIF1A (0.35) | GAAL3MBTL1IDO1HIF1ACYP2D6 | |
| Hydrochloric Acid SCHEMBL6633309 | 0.95 | GAA (0.36) | GAAL3MBTL1IDO1HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119308018-A | Chiral zinc-based metal halide monocrystal material and preparation method and application thereof | 江西铜业技术研究院有限公司 | 2025-01-14 | — | — | CN | claimed |
| US-20150218449-A1 | LIQUID CRYSTAL COMPOUND CONTAINING CYCLOPENTYL AND DIFLUOROMETHENEOXY LINKING GROUP, PREPARATION METHOD AND APPLICATION THEREOF | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATRIALS CO., LTD. (CN) | 2015-08-06 | — | — | US | claimed |
| US-6316575-B1 | MELT TRANSESTERIFICATION OF DIOL COMPOUND AND CARBOANTE COMPOUND USING CATALYST COMPRISING A PHOSPHORUS-CONTAINING BASIC COMPOUND QUATERNARY PHOSPHONIUM SALT TO FORM POLYCARBONATE | IDEMITSU KOSAN CO., LTD. (JP) | 2001-11-13 | — | — | US | claimed |
| EP-0329021-B1 | Preparation of advanced epoxy resins and dihydric phenols in the presence of phosphonium compounds | DOW CHEMICAL CO (US) | 1994-01-26 | — | — | EP | claimed |
| EP-0329021-A2 | Preparation of advanced epoxy resins and dihydric phenols in the presence of phosphonium compounds | THE DOW CHEMICAL COMPANY (US) | 1989-08-23 | — | — | EP | claimed |
| US-4808692-A | Preparation of advanced epoxy resins from epoxy resins and dihydric phenols in the presence of phosphonium compounds | THE DOW CHEMICAL COMPANY (US) | 1989-02-28 | — | — | US | claimed |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4504739-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119308018-A | Chiral zinc-based metal halide monocrystal material and preparation method and application thereof | 江西铜业技术研究院有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20240182908-A1 | DEOXYRIBONUCLEOSIDE OR DEOXYRIBONUCLEOTIDE HAVING NOVEL ARTIFICIAL BASE APPLICABLE TO SCREENING FOR DNA APTAMER, AND NUCLEIC ACID CONTAINING THE SAME | TAGCYX BIOTECHNOLOGIES INC (JP) | 2024-06-06 | — | — | US | disclosed |
| EP-4265726-A1 | DEOXYRIBONUCLEOSIDE OR DEOXYRIBONUCLEOTIDE HAVING NOVEL ARTIFICIAL BASE CAPABLE OF BEING USED FOR SCREENING FOR DNA APTAMER, AND NUCLEIC ACID CONTAINING SAME | TAGCyx Biotechnologies Inc. (JP) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-116635038-A | Deoxyribonucleosides, deoxyribonucleotides, and nucleic acids having novel artificial bases useful for DNA aptamer screening | 塔古西库斯生物株式会社 | 2023-08-22 | — | — | CN | disclosed |
| US-4808692-A | Preparation of advanced epoxy resins from epoxy resins and dihydric phenols in the presence of phosphonium compounds | THE DOW CHEMICAL COMPANY (US) | 1989-02-28 | — | — | US | disclosed |
| US-4407823-A | ANTIINFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1983-10-04 | — | — | US | disclosed |
| EP-0007319-B1 | INDAN-1-CARBOXYLIC ACID DERIVATIVES,PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1981-09-16 | — | — | EP | disclosed |
| US-4206140-A | INSECTICIDES, ANTHELMINTICS | ROUSSEL UCLAF (FR) | 1980-06-03 | — | — | US | disclosed |
| EP-0007319-A1 | Indan-1-carboxylic acid derivatives,process for their preparation and pharmaceutical preparations containing these compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-02-06 | — | — | EP | disclosed |
| US-4101574-A | Cyclopropanecarboxylic acid chlorides | ROUSSEL UCLAF (FR) | 1978-07-18 | — | — | US | disclosed |
| US-3997586-A | Cyclopropanecarboxylic acids and esters | ROUSSEL-UCLAF (FR) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | GAA 956/4885L3MBTL1 4197/4885IDO1 4795/4885 |
| US-20240182908-A1 | DEOXYRIBONUCLEOSIDE OR DEOXYRIBONUCLEOTIDE HAVING NOVEL ARTIFICIAL BASE APPLICABLE TO SCREENING FOR DNA APTAMER, AND NUCLEIC ACID CONTAINING THE SAME | RNASEL, HNRNPL, DCLRE1B | GAA 2368/4885L3MBTL1 722/4885IDO1 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.